References
1. Aboyans V, Ricco JB, Bartelink ML, et al. [2017 ESC Guidelines on
the Diagnosis and Treatment of Peripheral Arterial Diseases, in
collaboration with the European Society for Vascular Surgery (ESVS)].Kardiol Pol . 2017;75(11):1065-1160. Wytyczne ESC dotyczace
rozpoznawania i leczenia chorob tetnic obwodowych w 2017 roku,
przygotowane we wspolpracy z ESVS. doi:10.5603/KP.2017.0216
2. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for
the management of valvular heart disease. Eur Heart J . Sep 21
2017;38(36):2739-2791. doi:10.1093/eurheartj/ehx391
3. Valgimigli M, Bueno H, Byrne RA, et al. [2017 ESC focused update on
dual antiplatelet therapy in coronary artery disease developed in
collaboration with EACTS.]. Kardiol Pol . 2017;75(12):1217-1299.
Uaktualnione stanowisko ESC dotyczace stosowania podwojnej terapii
przeciwplytkowej w chorobie wiencowej w 2017 roku, przygotowane we
wspolpracy z EACTS. doi:10.5603/KP.2017.0224
4. Ricotta JJ, Aburahma A, Ascher E, et al. Updated Society for Vascular
Surgery guidelines for management of extracranial carotid disease:
executive summary. J Vasc Surg . Sep 2011;54(3):832-6.
doi:10.1016/j.jvs.2011.07.004
5. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with
single, dual, or triple therapy with warfarin, aspirin, and clopidogrel
in patients with atrial fibrillation. Arch Intern Med . Sep 13
2010;170(16):1433-41. doi:10.1001/archinternmed.2010.271
6. van Rein N, Heide-Jorgensen U, Lijfering WM, Dekkers OM, Sorensen HT,
Cannegieter SC. Major Bleeding Rates in Atrial Fibrillation Patients on
Single, Dual, or Triple Antithrombotic Therapy. Circulation . Feb
5 2019;139(6):775-786. doi:10.1161/CIRCULATIONAHA.118.036248
7. Piazza G, Nguyen TN, Cios D, et al. Anticoagulation-associated
adverse drug events. Am J Med . Dec 2011;124(12):1136-42.
doi:10.1016/j.amjmed.2011.06.009
8. Franchi C, Antoniazzi S, Proietti M, Nobili A, Mannucci PM,
Collaborators S-A. Appropriateness of oral anticoagulant therapy
prescription and its associated factors in hospitalized older people
with atrial fibrillation. Br J Clin Pharmacol . Sep
2018;84(9):2010-2019. doi:10.1111/bcp.13631
9. Moudallel S, Steurbaut S, Cornu P, Dupont A. Appropriateness of DOAC
Prescribing Before and During Hospital Admission and Analysis of
Determinants for Inappropriate Prescribing. Front Pharmacol .
2018;9:1220. doi:10.3389/fphar.2018.01220
10. Zhang ZX, van de Garde EMW, Sohne M, Harmsze AM, van den Broek MPH.
Quality of clinical direct oral anticoagulant prescribing and
identification of risk factors for inappropriate prescriptions. Br
J Clin Pharmacol . Aug 2020;86(8):1567-1574. doi:10.1111/bcp.14264
11. Dreijer AR, Diepstraten J, Bukkems VE, et al. Anticoagulant
medication errors in hospitals and primary care: a cross-sectional
study. Int J Qual Health Care . Jun 1 2019;31(5):346-352.
doi:10.1093/intqhc/mzy177
12. Bordet R, Gautier S, Le Louet H, Dupuis B, Caron J. Analysis of the
direct cost of adverse drug reactions in hospitalised patients.Eur J Clin Pharmacol . Mar 2001;56(12):935-41.
doi:10.1007/s002280000260
13. van der Hooft CS, Dieleman JP, Siemes C, et al. Adverse drug
reaction-related hospitalisations: a population-based cohort study.Pharmacoepidemiol Drug Saf . Apr 2008;17(4):365-71.
doi:10.1002/pds.1565
14. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM, Group HS.
Frequency of and risk factors for preventable medication-related
hospital admissions in the Netherlands. Arch Intern Med . Sep 22
2008;168(17):1890-6. doi:10.1001/archinternmed.2008.3
15. Essebag V, AlTurki A, Proietti R, et al. Concomitant anti-platelet
therapy in warfarin-treated patients undergoing cardiac rhythm device
implantation: A secondary analysis of the BRUISE CONTROL trial.Int J Cardiol . Aug 1 2019;288:87-93.
doi:10.1016/j.ijcard.2019.04.066
16. Kilic S, Celik A, Cekirdekci E, et al. The Prevalence and Risks of
Inappropriate Combination of Aspirin and Warfarin in Clinical Practice:
Results From WARFARIN-TR Study. Balkan Med J . Jan 1
2019;36(1):17-22. doi:10.4274/balkanmedj.2017.1472
17. So CH, Eckman MH. Combined aspirin and anticoagulant therapy in
patients with atrial fibrillation. Journal of thrombosis and
thrombolysis . 2017;43(1):7-17.
18. De Caterina R, Ammentorp B, Darius H, et al. Frequent and possibly
inappropriate use of combination therapy with an oral anticoagulant and
antiplatelet agents in patients with atrial fibrillation in Europe.Heart . 2014;100(20):1625-1635.
19. Watanabe E, Yamamoto M, Kodama I, et al. Net clinical benefit of
adding aspirin to warfarin in patients with atrial fibrillation:
Insights from the J-RHYTHM Registry. Int J Cardiol . Jun 1
2016;212:311-7. doi:10.1016/j.ijcard.2016.03.008
20. van Uden R, van den Broek MPH, Houtenbos I, et al. Unintentional
guideline deviations in hospitalized patients with two or more
antithrombotic agents: an intervention study. Eur J Clin
Pharmacol . Jul 28 2021;doi:10.1007/s00228-021-03185-y
21. Eyileten C, Postula M, Jakubik D, et al. Non-Vitamin K Oral
Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial
Fibrillation with Elective or Urgent Percutaneous Coronary Intervention:
A Meta-Analysis with a Particular Focus on Combination Type. J
Clin Med . Apr 14 2020;9(4)doi:10.3390/jcm9041120
22. Gargiulo G, Goette A, Tijssen J, et al. Safety and efficacy outcomes
of double vs. triple antithrombotic therapy in patients with atrial
fibrillation following percutaneous coronary intervention: a systematic
review and meta-analysis of non-vitamin K antagonist oral
anticoagulant-based randomized clinical trials. Eur Heart J . Dec
7 2019;40(46):3757-3767. doi:10.1093/eurheartj/ehz732
23. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic Therapy after
Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J
Med . Apr 18 2019;380(16):1509-1524. doi:10.1056/NEJMoa1817083
24. Dreijer AR, Kruip M, Diepstraten J, et al. Effect of antithrombotic
stewardship on the efficacy and safety of antithrombotic therapy during
and after hospitalization. PLoS One . 2020;15(6):e0235048.
doi:10.1371/journal.pone.0235048